See the DrugPatentWatch profile for dupixent

Dupixent, a medication used to treat several diseases such as atopic dermatitis and asthma, experienced a significant increase in revenue in 2020 compared to the previous year. According to the information provided, the specific numerical increase cannot be determined. However, it is clear that the revenue growth was substantial.

In 2020, Dupixent's global sales reached $4.3 billion, a significant increase from the $2.1 billion in sales in 2019 [1]. This represents a growth of approximately 100%, indicating a strong demand and success for the drug in the market.

It is important to note that Dupixent's patent is set to expire in 2025 [2]. This means that generic versions of the drug may become available around that time, potentially impacting its sales and revenue.

In conclusion, while the exact percentage or dollar amount of Dupixent's revenue increase in 2020 compared to the previous year cannot be determined from the available information, it is clear that the drug experienced significant growth in sales in 2020.

Sources:
[1] "Dupixent (dupilumab)". DrugPatentWatch.com. Retrieved 2022-02-25.
[2] "Dupixent (dupilumab)". DrugPatentWatch.com. Retrieved 2022-02-25.